Efficacy of DNA hypomethylating capacities of 5-aza-2′-deoxycytidine and its alpha anomer

被引:19
|
作者
Fojtova, Miloslava
Piskala, Alois
Votruba, Ivan
Otmar, Miroslav
Bartova, Eva
Kovarik, Ales
机构
[1] Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic
[2] Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic
关键词
DNA methylation; hypomethylation drug; 5-aza-2 '-deoxycytidine; anomers; cancer;
D O I
10.1016/j.phrs.2006.09.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this paper, we have compared hypomethylating ability of classical beta-D-anomer of 5-aza-2'-deoxycytidine (5-aza-CdRf) and its alpha anomer in cell cultures. Alpha anomers of nucleosides generally exhibit low biological activity compared to their beta counterparts. It is reported that alpha anomer of 5-aza-CdRf efficiently hypomethylated genomic DNA in human T-lymphoblastoid CCRF-CEM cells. Satellite 2 and 18S rDNA were hypomethylated by alpha anomer at concentrations comparable to the beta form. However, the toxicity of the alpha anomer was 4-fold less than that of beta form. Contrast to CCRF-CEM the A549 lung carcinoma cells, possessing negligible level of methylation at repetitive loci, were highly resistant to 5-aza-CdRf treatment suggesting that global genomic methylation might be needed to mediate cytotoxic effect of the drug. Possible mechanisms of inhibition of DNA methylation by alpha anomer are discussed. In conclusion, alpha anomer of 5-aza-CdRf displaying lower host cytotoxicity than the classical beta form may be of potential use in epigenetic therapy. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:16 / 22
页数:7
相关论文
共 50 条
  • [31] Effects of Treatment with the Hypomethylating Agent 5-aza-2′-deoxycytidine in Murine Type II Collagen-Induced Arthritis
    Petralia, Maria Cristina
    Mazzon, Emanuela
    Basile, Maria Sofia
    Cutuli, Marco
    Di Marco, Roberto
    Scandurra, Fabiola
    Saraceno, Andrea
    Fagone, Paolo
    Nicoletti, Ferdinando
    Mangano, Katia
    PHARMACEUTICALS, 2019, 12 (04)
  • [32] Pharmacologic myocardial egeneration using 5-Aza-2′deoxycytidine
    Ibrahim, E
    Chin, T
    Davis, J
    Kao, RL
    FASEB JOURNAL, 2002, 16 (04): : A491 - A491
  • [33] TOXICOLOGY IN MICE OF THE ANTILEUKEMIC AGENT 5-AZA-2'-DEOXYCYTIDINE
    MOMPARLER, RL
    FRITH, CH
    DRUG AND CHEMICAL TOXICOLOGY, 1981, 4 (04) : 373 - 381
  • [34] TRANSFORMATION AND METABOLIC EFFECTS OF 5-AZA-2'-DEOXYCYTIDINE IN MICE
    CIHAK, A
    VESELY, J
    HYNIE, S
    BIOCHEMICAL PHARMACOLOGY, 1980, 29 (21) : 2929 - 2932
  • [35] INVITRO CYTOTOXIC AND BIOCHEMICAL EFFECTS OF 5-AZA-2'-DEOXYCYTIDINE
    MOMPARLER, RL
    GOODMAN, J
    CANCER RESEARCH, 1977, 37 (06) : 1636 - 1639
  • [36] Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides
    Yoo, Christine B.
    Jeong, Shinwu
    Egger, Gerda
    Liang, Gangning
    Phiasivongsa, Pasit
    Tang, Chunlin
    Redkar, Sanjeev
    Jones, Peter A.
    CANCER RESEARCH, 2007, 67 (13) : 6400 - 6408
  • [37] 5-AZA-2'-DEOXYCYTIDINE (DAC) - THE EUROPEAN-EXPERIENCE
    DODION, P
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 68 - 68
  • [38] DEPRESSION OF DNA-SYNTHESIS IN MOUSE SPLEEN AFTER TREATMENT WITH 5-AZA-2'-DEOXYCYTIDINE
    CIHAK, A
    VESELY, J
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1979, 63 (04): : 1035 - 1039
  • [39] Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome
    Mund, C
    Hackanson, B
    Stresemann, C
    Lübbert, M
    Lyko, F
    CANCER RESEARCH, 2005, 65 (16) : 7086 - 7090
  • [40] Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2′-deoxycytidine
    Ding, Xiao-Lei
    Yang, Xiaojing
    Liang, Gangning
    Wang, Kai
    SCIENTIFIC REPORTS, 2016, 6